Personalis (NASDAQ:PSNL) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Personalis (NASDAQ:PSNL) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Several other research firms have also recently commented on PSNL. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. HC Wainwright increased their target price on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Guggenheim boosted their price target on shares of Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Morgan Stanley upped their price target on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Finally, Lake Street Capital reiterated a “buy” rating and set a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.57.

Personalis Trading Up 2.2%

Shares of PSNL stock opened at $8.02 on Friday. The company has a market capitalization of $712.21 million, a price-to-earnings ratio of -9.11 and a beta of 1.96. Personalis has a 1-year low of $2.83 and a 1-year high of $11.40. The stock’s fifty day simple moving average is $8.79 and its 200-day simple moving average is $7.21.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The firm had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. On average, sell-side analysts predict that Personalis will post -1.4 EPS for the current year.

Insider Buying and Selling at Personalis

In other Personalis news, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the transaction, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Aaron Tachibana sold 103,668 shares of the business’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This represents a 38.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Personalis

Several institutional investors and hedge funds have recently added to or reduced their stakes in PSNL. Legal & General Group Plc acquired a new position in Personalis during the second quarter valued at approximately $30,000. Ameritas Investment Partners Inc. bought a new stake in shares of Personalis during the 2nd quarter worth $34,000. BNP Paribas Financial Markets boosted its holdings in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the period. Alpha Wealth Funds LLC acquired a new position in Personalis in the 2nd quarter valued at $66,000. Finally, Farther Finance Advisors LLC bought a new position in Personalis in the 3rd quarter worth $66,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.